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Large case/control Genome-Wide Association Studies (GWAS)
often include groups of related individuals with known relationships.
When testing for associations at a given locus, current methods in-
corporate only the familial relationships between individuals. Here,
we introduce the chromosome-based Quasi Likelihood Score (cQLS)
statistic that incorporates local Identity-By-Descent (IBD) to in-
crease the power to detect associations. In studies robust to pop-
ulation stratification, such as those with case/control sibling pairs,
simulations show that the study power can be increased by over 50%.
In our example, a GWAS examining late-onset Alzheimer’s disease,
the p-values among the most strongly associated SNPs in the APOE
gene tend to decrease, with the smallest p-value decreasing from
1.23×10−8 to 7.70×10−9 . Furthermore, as a part of our simulations,
we reevaluate our expectations about the use of families in GWAS.
We show that, although adding only half as many unique chromo-
somes, genotyping affected siblings is more efficient than genotyping
randomly ascertained cases. We also show that genotyping cases with
a family history of disease will be less beneficial when searching for
SNPs with smaller effect sizes.
1. Introduction. Genome-Wide Association Studies (GWAS) of binary
traits can include related individuals from known pedigrees [Barrett et al.
(2008), Willer et al. (2008)]. In case–control studies, GWAS generally in-
crease power by collecting cases with affected relatives, and may therefore
find it cost-effective to genotype these related cases as well. Furthermore,
GWAS may target families because the appropriate association tests are
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robust to population stratification [Ewens, Li and Spielman (2008)], the
families have previously been collected for linkage analyses, the genetic vari-
ants can be called more accurately [Wang et al. (2007)], or the effects of
parental imprinting can be evaluated [Wilkinson, Davies and Isles (2007)].
There are two general approaches for evaluating GWAS with related indi-
viduals from known pedigrees [Ott, Kamatani and Lathrop (2011), Manichai-
kul et al. (2012)]. The first approach combines two independent tests, a
family-based test [Sham et al. (2002), Lange et al. (2003), Laird, Horvath and
Xu (2000)], such as the transmission-disequilibrium test, and a population-
based test of association. Methods exist for combining these two tests so the
resulting analysis is robust to population stratification [Zheng et al. (2010),
Won et al. (2012), Mirea et al. (2012), Manichaikul et al. (2012)]. The second
approach, which potentially sacrifices robustness for improved power, cal-
culates a single test statistic of association that accounts for the correlated
genotypes among relatives [Bourgain et al. (2003), Thornton and McPeek
(2007), Slager and Schaid (2001)]. Our focus is on the second approach and
we derive a single test statistic which can use principal components [Price
et al. (2006)] to correct for population stratification when necessary.
Until now, standard GWAS analyses have focused on the individual. For
each individual, a study records their genotype and disease status. If all in-
dividuals were unrelated, the appropriate test statistic would simply be the
correlation between an individual’s genotype and disease status [Hirschhorn
and Daly (2005)]. However, when some individuals are related, a test statis-
tic should correct for the dependence among genotypes and allow for the
minor allele frequency (MAF) at a causal SNP to be higher in controls with
affected relatives, as compared to randomly ascertained controls [Thorn-
ton and McPeek (2007), Bourgain et al. (2003), Zhu and Xiong (2012)].
The more-powerful Quasi-Likelihood Score (mQLS) statistic [Thornton and
McPeek (2007)], an extension of the QLS [Bourgain et al. (2003)], accom-
plishes both objectives. However, because these statistics consider only the
overall Identity By Descent (IBD) status between two individuals, they can-
not allow for the MAF at a causal SNP to be higher in controls that share
both alleles (IBD = 2) with an affected sibling, as compared to controls that
share no alleles (IBD = 0) with an affected sibling.
We introduce a GWAS analysis that takes a different perspective and fo-
cuses on the founder chromosomes within each family. For each founder chro-
mosome, we effectively identify its allele (at a given SNP) and the proportion
of individuals carrying the SNP from that chromosome who are affected.
This step is made possible by recent advances in IBD mapping and haplo-
typing [Browning and Browning (2010), Peters et al. (2012), He (2013)]. We
suggest a chromosome-based Quasi Likelihood Score (cQLS) statistic that,
at its simplest, measures the correlation between a binary indicator for the
minor allele and the proportion of individuals affected. Formally, this test
CQLS 3
statistic is a partial score statistic from the retrospective likelihood that
includes local IBD status among the observed data. The cQLS effectively
leverages local IBD to improve power in GWAS with a large number of
family-based controls. Furthermore, the derivation of the cQLS as a score
statistic shows how to appropriately handle families of arbitrary pedigrees,
include phenotype data from ungenotyped relatives, accommodate covari-
ates, and allow for arbitrary models (e.g., logistic, liability threshold) linking
disease risk and genotype status. In addition to these useful features, the
cQLS also permits permutation-based measures of statistical significance.
Accounting for relatedness in permutation methods of subject-centric ap-
proaches has proven exceptionally difficult [Wang (2011)].
In the next section, we define cQLS, describe the simulated data sets for
testing its performance, and introduce a GWAS of Late-Onset Alzheimer’s
Disease (LOAD) conducted by the National Institute of Aging and the Na-
tional Cell Repository for Alzheimer’s Disease (NIA-LOAD/NCRAD) [Lee
et al. (2008), Wijsman et al. (2011)]. In the third section, we evaluate the per-
formance of the cQLS in simulated data sets and the NIA-LOAD/NCRAD
data set. In addition to showing the potential benefit of cQLS, simulations
evaluate the power gained by genotyping affected siblings, as compared to
randomly ascertained cases, and demonstrate the diminished benefit of re-
cruiting cases with a family history of disease when searching for SNPs with
small effects [Ionita-Laza and Ottman (2011), Hattersley and McCarthy
(2005), Teng and Risch (1999)]. In the final section, we conclude with a
brief discussion.
2. Methods.
2.1. cQLS: Definition. We consider a case–control study that contains
NFam families, labeled j = 1, . . . ,NFam. Within family j, all genotyped chro-
mosomes are assumed to arise from a family-specific set of nj founder chro-
mosomes, labeled k = 1, . . . , nj . We denote the total number of chromosomes
by NT :
NT =
∑
j
nj.(2.1)
For a given SNP, we let Yjk = 1 if the unique founder chromosome k in family
j has a minor allele, and Yjk = 0 otherwise. Note that the subscripts “j1k”
and “j2k” refer to different founder chromosomes from different families. For
our discussion here, we will assume that Yjk is uniquely identifiable given
the observed genetic data and that we can identify, with certainty, those
individuals in family j who inherited the SNP from founder chromosome k.
Both assumptions will be relaxed in the Appendix. Furthermore, we will let
Tjik′k = 1 if the k
′th copy (k′ ∈ {1,2}) of the specified SNP in individual i
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is descended from founder chromosome k, and Tjik′k = 0 otherwise. We let
Aji = 1 if individual i is affected, and Aji = 0 otherwise.
For each founder SNP, we have Yjk, indicating the presence or absence of
a minor allele, and Cjk =
∑
i,k′ Tjik′kAji, a count of the number of affected
individuals with that SNP. If we expect that the minor allele increases dis-
ease risk, then the presence of a minor allele should be associated with a
larger number of affected individuals. Therefore, the squared correlation be-
tween Yjk and Cjk should be high. The proposed test statistic is a variation
of this squared correlation.
Instead of using the count, Cjk, we use a version that normalizes each
individual’s affection status to their expected affection status under the null
hypothesis of no association,
Zjk =
∑
i
∑
k′
Tjik′k
(
Aji−
πˆ0
1− πˆ0
(1−Aji)
)
,(2.2)
where πˆ0 is our estimate of the prevalence of the disease in the population.
We presume there are established estimates of πˆ0 available in the literature.
In the Appendix, we show how we can modify the expected affection status
when other characteristics are known. We further show how we can make
specific individuals, such as those with a family history of disease, carry
more weight in the analysis by effectively increasing their contribution to
Zjk. We denote the average of all observed values of Zjk by
Z¯ ≡
∑
j,kZjk
NT
.(2.3)
Finally, we define a normalized version of the allele for chromosome k,
Y †jk = Yjk − φˆ,(2.4)
where
φˆ≡
∑
j,k Yjk
NT
(2.5)
and is our estimate of φ, the minor allele frequency in the population, under
the null hypothesis. As promised, our chromosome-based Quasi-Likelihood
Score (cQLS) statistic is then proportional to the squared correlation be-
tween Y † and Z,
cQLS≡
(
∑
j,k(Zjk − Z¯)Y
†
jk)
2∑
j,k(Zjk − Z¯)
2φˆ(1− φˆ)
.(2.6)
Because var(Y †jk) is calculated as φˆ(1− φˆ), equation (2.6) requires the as-
sumption of the Hardy–Weinberg Equilibrium (HWE). Therefore, the ver-
sion of cQLS defined by equation (2.6) is appropriate in an ideal scenario
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where the genotypes and phenotypes of all individuals are known, Yjk can
be identified for all families and chromosomes, and HWE holds. In the
Appendix, we define a more robust cQLS that allows for violations in all
three assumptions.
2.2. Assigning chromosomes. To calculate cQLS, we need to determine
Tjik′k, or the identity of the two chromosomes in individual i for all i, j, k
′,
and k at each SNP. We perform this calculation in three steps. First, we
phase subjects using BEAGLE [Browning and Browning (2011)], a software
package for analysis of large-scale genetic data sets. Second, we detect shared
segments within a family using GERMLINE [Gusev et al. (2009)], a software
package for discovering long shared segments of Identity-By-Descent (IBD).
In the third step, we convert the IBD status to Tjik′k. The algorithm for this
final step is described in Appendix B.4.
2.3. Simulations. Our three aims are to (1) assess the benefit of chromo-
some-based association tests (2) assess the value of genotyping an affected
sibling and (3) assess the benefit of genotyping cases known to have affected
siblings.
For our simulations, we assume that the liability threshold model accu-
rately describes disease risk. In the liability threshold model, a complex dis-
ease results from an underlying, normally distributed, phenotype, or liability.
When an individual’s liability exceeds a specific threshold, the individual is
affected. In our scenario, the liability, Lj , for individuals in nuclear family
j can be described by a linear function of their genotypes Gj , where Gji
is the number of minor alleles for individual i, Gj = [Gj1 · · · GjNj ]
t, and
the superscript t indicates transpose. Here, Ej accounts for environmental
factors, while Fj accounts for background genetic correlation:
Lj = βG(Gj − 2φ) +Ej + βFFj ,(2.7)
where 

Ej1
Ej2
...
EjNj

∼N




0
0
...
0

 ,


1 0 · · · 0
0 1 · · · 0
...
0 0 · · · 1



(2.8)
and 

Fj1
Fj2
Fj3
...
FjNj


∼N




0
0
0
...
0

 ,


1 0 0.5 · · · 0.5
0 1 0.5 · · · 0.5
0.5 0.5 1 · · · 0.5
...
...
...
. . .
...
0.5 0.5 0.5 · · · 1



 .(2.9)
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Here, Nj is the number of individuals in family j, and individuals j1 and
j2 are the parents. The liability threshold model will assign all individuals
with Lji exceeding the population’s 95th percentile to have the disease. We
chose βG so that the corresponding OR for each additional minor allele
was between 1.02 and 1.36. We chose βF so that the sibling recurrence risk
ratio, λS , was 1.5, 2 or 5 when βG = 0. Note that the magnitude of the sibling
recurrence risk ratio, as defined here, is independent of the strength of the
tested SNP. To calculate βF , we numerically solved the following equation:∫ ∞
F−12 (0.95)
[∫ ∞
F−12 (0.95)
f1(x|y)∂x
]
f2(y)∂y = 0.05λS ,(2.10)
where F2 and f2 are the cumulative distribution and density of N(0,1+β
2
F ),
and f1(x|y) is the density of N(β
2
F y/(2(1 + β
2
F )), (1 + 2β
2
F + 1.75β
4
F )/(1 +
β2F )). The MAF in the population was fixed at 0.1, and genotypes were
simulated under HWE.
Our simulated studies, summarized in Table 1, collect families and/or un-
related cases and controls. The first five studies all start by identifying and
genotyping 10,000 unrelated, randomly ascertained controls (R.A. controls).
By randomly ascertained, we mean that we have no knowledge of their fam-
ily history of disease. Study 1 further genotypes 5000 unrelated, randomly
ascertained cases (R.A. cases). Study 2 genotypes 5000 unrelated cases (F.H.
cases) with a family history of disease, specifically with an affected sibling.
Study 3 genotypes both the 5000 R.A. cases and the 5000 F.H. cases. Study
4 genotypes 10,000 R.A. cases and 5000 F.H. cases. Studies 5 and 6 geno-
type 1 sibling of each proband. Study 5 genotypes the 5000 R.A cases, 5000
F.H. cases and their affected siblings. Study 6 includes 10,000 unrelated
cases with an unaffected sibling and their unaffected siblings. Study 7 geno-
types multiple relatives of each proband. Specifically, study 7 genotypes the
10,000 F.H. cases, their affected siblings and two unaffected siblings. Studies
6 and 7 highlight the potential power gain for cQLS in scenarios where only
family-based controls are available.
For various combinations of βG, λS and study design, we simulated 10,000
data sets and calculated the FBAT test statistic [Laird, Horvath and Xu
(2000)], mQLS [Bourgain et al. (2003), Thornton and McPeek (2007)] and
cQLS for each data set. The power was defined as the proportion of p-values
that were below the 10−7 threshold, a common threshold for GWAS. By
using 10,000 data sets, the standard errors for our estimates of power are
bounded by 0.01. A short description of FBAT and mQLS are provided
in Appendix A. Previous comparisons [Manichaikul et al. (2012)] of the
available test statistics have demonstrated that, among currently available
options, mQLS is consistently a top performer and the appropriate refer-
ence for comparison. For all simulations, the cQLS statistic was calculated
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Table 1
Each evaluated study design, labeled 1 through 7, genotypes different types of cases and
controls. The first set of columns lists the number of randomly ascertained cases
(Random), identified cases—or probands—with a family history (Fam. His.), and
affected siblings of probands (Sib. 1) genotyped for the given study. The second set of
columns lists the number of randomly ascertained controls (Rand.), unaffected “older”
siblings (Sib. 1) and unaffected “younger” siblings (Sib. 2) genotyped for the given study.
Studies 1 and 2 are used to assess the benefit of genotyping individuals with a family
history of disease. Studies 3, 4 and 5 are used to assess the benefit of genotyping siblings
of probands. Studies 6 and 7 are used to assess chromosome-based tests
Cases Controls
Study Random Fam. His. Sib. 1 Random Sib. 1 Sib. 2
1 5000 0 0 10,000 0 0
2 0 5000 0 10,000 0 0
3 5000 5000 0 10,000 0 0
4 10,000 5000 0 10,000 0 0
Multiple family members genotyped
5 5000 5000 5000 10,000 0 0
6 0 10,000 0 0 10,000 0
7 0 10,000 10,000 0 10,000 10,000
using the true IBD of all chromosomes within each family. Moreover, the
tested SNP was assumed to be the causal SNP. We also evaluated the effect
of mistakes in IBD assignment on the power of the cQLS statistic. For a
proportion of sibling sets, we randomly assigned the IBD status for each in-
dividual in that set, ensuring only that the IBD status was consistent with
the observed genotypes. We then recalculated the power for Studies 6 and 7
with λS = 1.5. We examined the scenarios where 2%, 5% and 8% of sibling
sets were allowed to have errors.
To test the accuracy of the p-value, we simulated 107 data sets under the
null distribution for study designs 5, 6 and 7, where the mQLS and cQLS
statistics differ, assuming λS = 5. For computational efficiency, we included
only 1000 subjects and only examined larger thresholds of 10−3 and 10−4.
2.4. NIA-LOAD. The details of the NIA-LOAD/NCRAD GWAS of Late
Onset Alzheimer’s Disease (LOAD) have been described elsewhere [Wijs-
man et al. (2011)]. Briefly, the study recruited families with multiple af-
fected individuals. Specifically, probands were required to have a diagnosis
of Alzheimer’s Disease after the age of 60, have a sibling with a similar di-
agnosis and an additional biologically-related family member available for
genotyping. In these families, additional relatives over the age of 50 were
recruited regardless of cognitive status. Study participants were then geno-
typed using Illumina’s Human610Quadv1B BeadChips (Illumina, San Diego,
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CA, USA). We augmented the genotypes by imputing SNPs in the APOE
region that have been previously associated with LOAD [Bertram et al.
(2007)] using IMPUTE2 software version 2.2.2 [Howie, Donnelly and Mar-
chini (2009)], with prephasing by SHAPEIT software version 1 [Delaneau,
Zagury and Marchini (2013)] and version 3 of the 1000 Genomes Project
data as the reference set. At each imputed SNP, we assigned the most likely
genotypes that were consistent with IBD status. In order to create a study
guaranteed to be robust to population stratification, we focused on 115 sets
of siblings and pruned each set so that it had an equal number of cases and
controls.
3. Results.
3.1. cQLS vs mQLS. Chromosome-based test statistics had higher power,
as compared to mQLS and FBAT, to detect associations when the study in-
cluded cases and controls from the same family (Figure 1). We first consider
simulations where the disease had a relatively low sibling relative risk of
λS = 1.5. If the GWAS included pairs of siblings (study 6), one affected and
one unaffected, then a SNP that would be detected by cQLS in 75% of such
studies would only be detected by QLS in 51% [Figure 1(a)]. In studies that
included sets of four siblings (study 7), with each set including two affected
and two unaffected individuals, when cQLS provided a power of 0.75, QLS
provided a power of 0.36 [Figure 1(c)]. When we simulated a disease with
a high sibling relative risk (λS = 5), the power gained from using cQLS de-
creased. For study designs 6 and 7, mQLS achieved a power of 0.59 and 0.63
for SNPs where cQLS achieved a power of 0.75 [Figure 1(b), (d)].
Errors in IBD assignment decreased the power for association tests using
cQLS. With an error rate of 2%, tests based on cQLS still had higher power
for studies 6 and 7. However, with an error rate of 5%, cQLS performed no
better than the other two test statistics in study 6 (λS = 1.5). Specifically,
when cQLS had a power of 0.75 (SE = 0.01), QLS provided a similar power
of 0.72 (SE = 0.01). When the error rate reached 8%, the three test statistics
performed similarly in study 7 (λS = 1.5), with QLS achieving a power of
0.74 (0.01) when cQLS had a power of 0.75 (0.01).
Simulations suggest that the type-I error for the cQLS statistic matched
the chosen α threshold when simulating data from the null distribution
(Table 2).
3.2. Genotyping F.H. cases vs R.A. cases. Genotyping cases with a fam-
ily history of disease provides a study with significantly higher power than
genotyping randomly ascertained cases. For a disease with a low sibling rel-
ative risk (λS = 1.5), when the effect size for a SNP was large enough so that
the study with all F.H. cases (study 2) had a power of 0.75, a study with
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Fig. 1. The power for cQLS (blue), mQLS (red) and FBAT (black) to detect the associ-
ation between a SNP and the disease as a function of the OR when (a) λS = 1.5 in study
6, (b) λS = 5 in study 6, (c) λS = 1.5 in study 7 and (d) λS = 5 in study 7. Studies 6 and
7 correspond to genotyping pairs of siblings and groups of four siblings, respectively. λS is
the sibling relative risk of the disease.
Table 2
The proportions of 107 null simulations where the cQLS, mQLS and FBAT p-values are
below the specified α threshold. With 107 simulations, the standard errors for our
empirical α-levels of 10−3 and 10−4 are approximately 10−5 =
√
10−3/107 and
3× 10−6 =
√
10−4/107
cQLS mQLS FBAT
Study α= 10−3 α= 10−4 α= 10−3 α= 10−4 α= 10−3 α= 10−4
5 9.81× 10−4 9.65× 10−5 9.79× 10−4 9.03× 10−5 9.44× 10−4 8.38× 10−5
6 9.80× 10−4 9.25× 10−5 1.00× 10−3 1.08× 10−4 9.56× 10−4 1.04× 10−4
7 9.70× 10−4 1.00× 10−4 9.78× 10−4 9.68× 10−5 9.62× 10−4 9.28× 10−5
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Fig. 2. (a) The power to detect the association between a SNP and the disease, as a
function of OR, when the study compares 10,000 randomly ascertained controls with either
5000 R.A. cases (red, study 1) or 5000 F.H. cases (blue, study 2) when the sibling relative
risk, λS , is 1.5. (b) Same, but with λS = 5. For tests of unrelated individuals, all QLS
statistics give identical results.
all R.A. cases (study 1) had a power of only 0.20 [Figure 2(a)]. However,
as we increase the total heritability, shrinking the proportion of heritability
attributable to the tested SNP, the power gained from using F.H. cases is
decreased. When λS = 5, a SNP with a power of 0.75 in study 2 would have
had a power of 0.55 [Figure 2(b)] in study 1. For interpretation, recall that
the sibling relative risk (λS) reflects the heritability from genetic variants
other than the tested SNP. Therefore, as Figure 2(a) and 2(b) show, the
power of study 1, which collects R.A. cases, does not depend on λS , but
only on the relative risk of the tested SNP.
3.3. Genotyping affected sibling. Genotyping the affected siblings of F.H.
cases increases the power. The additional genotyping of 5000 siblings, or
moving from study 3 and a simple score test to study 5 and cQLS, will
increase the power to detect a SNP with OR= 1.15 from 0.57 to 0.75 [Fig-
ure 3(a)]. Each sibling, on average, only offers one new chromosome, but
siblings are also F.H. cases and, as such, are enriched for the causal allele.
Therefore, genotyping the 5000 siblings promises higher power than genotyp-
ing an additional 5000, unrelated, but randomly ascertained cases. Moving
from study 3 to study 4, which includes 10,000 R.A. cases and 5000 F.H.
cases, only increases the power from 0.57 to 0.63 [Figure 3(a)]. In studies
with a mixture of F.H. cases and R.A. cases, such as study 3, the power
of a standard association test can be improved by appropriately upweight-
ing F.H. cases through use of either mQLS or cQLS. When moving from
study 3 and cQLS to study 5 and cQLS, the power gain is less impressive,
increasing from 0.60 to 0.75 [Figure 3(c)]. When the total heritability is
high and λS = 5, mQLS and cQLS overweight the F.H. cases, and includ-
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Fig. 3. (a) The power to detect the association between a SNP and the disease, as a
function of OR, when the study compares 10,000 randomly ascertained controls with either
5000 R.A. cases + 5000 F.H. cases (blue, study 3), 10,000 R.A. cases + 5000 F.H. cases
(purple, study 4) or 5000 R.A. cases+ 5000 pairs of affected siblings (red, study 5) given
a sibling relative risk, λS , of 1.5 and all tests based on the score statistic. (b) Same, but
with λS = 5. (c) The power when the study compares 10,000 R.A. controls and either 5000
R.A. cases+ 5000 F.H. cases and the score statistic (blue), 5000 R.A. cases+ 5000 F.H.
cases and cQLS (purple), or 5000 R.A. cases+5000 pairs of affected siblings and the cQLS
(red) given a sibling relative risk, λS , of 1.5. (d) Same, but with λS = 5.
ing information about ungenotyped individuals can potentially lower power
[Figure 3(d)].
3.4. LOAD. In addition to the simulations, we tested 11 SNPs in the
APOE region of chromosome 19 for an association with LOAD in partici-
pants of the NIA-LOAD/NCRAD GWAS. Table 3 shows that eight of these
11 SNPs were associated with LOAD at a p-value below 0.05. In 7 of these
8 SNPs, the test based on the cQLS statistic resulted in a lower p-value, as
compared to using the mQLS or FBAT statistic. However, all three meth-
ods provide similar evidence that these SNPs are associated with Alzheimer’s
disease. For the two most strongly associated SNPs, rs429358 and rs4420638,
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Table 3
The p-values test from association tests of Late-Onset Alzheimer’s Disease and SNPs in
the APOE region among the NIA-LOAD/NCRAD population. The first three columns
indicate SNP ID, chromosome and position. The last three columns indicate the p-values
calculated from the mQLS, FBAT and cQLS statistics
SNP Chr. Position mQLS p-value FBAT p-value cQLS p-value
rs4806173 19 36,024,925 8.5× 10−1 7.7× 10−1 9.1× 10−1
rs12984928 19 36,029,852 8.5× 10−1 7.7× 10−1 9.1× 10−1
rs6857 19 45,392,254 6.0× 10−5 5.8× 10−6 2.0× 10−5
rs157582 19 45,396,219 4.7× 10−5 4.8× 10−6 1.4× 10−5
rs449647 19 45,408,564 1.9× 10−1 2.1× 10−1 7.5× 10−2
rs440446 19 45,409,167 1.8× 10−2 2.4× 10−2 2.1× 10−2
rs429358 19 45,411,941 1.2× 10−8 5.9× 10−8 7.7× 10−9
rs4420638 19 45,422,946 5.2× 10−7 1.1× 10−6 1.8× 10−7
rs157580 19 50,087,106 3.9× 10−2 3.2× 10−2 1.8× 10−2
rs2075650 19 50,087,459 3.0× 10−4 7.1× 10−5 1.7× 10−4
rs405509 19 50,100,676 4.5× 10−2 2.3× 10−2 4.2× 10−2
the p-values were reduced from 1.23−8 and 5.23−7 based on the mQLS statis-
tic, or 5.9−8 and 1.2−6 based on the FBAT statistic, to 7.70−9 and 1.79−7
based on the cQLS statistic.
4. Discussion. Our primary objective was to introduce the chromosome-
based Quasi-likelihood Score (cQLS) statistic and demonstrate that it can
offer increased power to detect associations in GWAS with related individu-
als. Specifically, in studies designed to be robust to population stratification,
such as those including sibling sets equally divided between cases and con-
trols, statistical power can be increased by over 50%. The new statistic can
also be applied to less robust study designs, but, like GWAS with unrelated
individuals, would then require adjusting for population-eigenvectors. The
derivation of cQLS as a partial likelihood shows how to easily adjust for
covariates in both logistic and liability-threshold models.
Although our evaluation has focused on single SNP tests with fixed thresh-
olds for statistical significance (e.g., 10−7), cQLS can offer a key, additional
advantage when testing groups of SNPs in linkage disequilibrium. In GWAS
with unrelated individuals, genotypes can be permuted among individuals to
obtain permutation-based measures of significance. In GWAS with related
individuals, standard methods are not appropriate, as individuals are not
independent [Wang (2011)]. However, the founder chromosomes are inde-
pendent and, therefore, it is straightforward to apply permutation methods
with cQLS in GWAS of related individuals.
In addition to illustrating the improved power, we designed our simula-
tions to reevaluate our expectations about the use of families in GWAS.
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First, affected siblings are often not genotyped because adding, on average,
only one unique chromosome to the study is thought not to be worth the cost.
However, we show that the power gained from genotyping an affected sibling
can actually exceed the power from genotyping a randomly ascertained case.
Second, it is well known that studies will have higher power when includ-
ing cases (F.H. cases) with a family history of disease. F.H. cases should
be enriched with disease-causing variants. However, we show that when a
disease is highly heritable, the enrichment for any specific disease-causing
variant is weaker. Thus, the benefit from genotyping cases with a family
history of disease is lower, as demonstrated by our comparison of diseases
with λS = 1.5 and λS = 5.
Like mQLS, cQLS offers the ability to use phenotyped, but not genotyped
family members. Such an advantage could also be gained by imputing the
genotype of such individuals and then performing the GWAS using the entire
population, with appropriate adjustment for the uncertainty introduced by
imputation. However such methods are not easily available and would still
not offer the other benefit of cQLS, identifying local IBD.
Although cQLS requires calculating haplotypes for determining IBD, the
test statistic still focuses on finding associations with single SNPs as opposed
to haplotypes. A haplotype analysis [Akey, Jin and Xiong (2001)], which
looks for associations with a specific haplotype, will decrease power when
the causal SNP is directly genotyped, as is likely to be the case when using
dense arrays or sequencing. However, having identified the haplotypes, this
information can be used to adjust for local ancestry instead of using a more
global principal components approach [Wang et al. (2011)].
The cQLS has limitations. First, the statistic will lose power in the pres-
ence of IBD error. In our examples, we found an error rate of 5% was large
enough to offset the benefit of cQLS in the smaller studies. A second issue
is that this new statistic requires a larger computational investment. Specif-
ically, the first three steps of phasing, detecting shared segments of IBD
and calculating Tjik′k required a total of 8.8 hours on a single 2.8 GHz In-
tel X5660 processor for the NIA-LOAD/NCRAD GWAS containing 575003
SNPs. After these initial steps, calculating the cQLS statistic for the NIA-
LOAD/NCRAD GWAS required only 3.2 minutes. In comparison, mQLS
required 70.4 minutes and FBAT required 11.1 minutes. Both mQLS and
FBAT required less time by dividing the genome into 22 regions. For mQLS,
we divided the genome into 22 intervals with an equal number of SNPs and
for FBAT, we divided the genome into chromosomes. The mQLS program
was not designed to handle GWAS, and we would expect that if optimized,
performing an mQLS analysis would require less computational time than a
cQLS analysis.
The benefit of cQLS depends on study design. For those designs that
include mixtures of family-based and randomly ascertained controls, the in-
creased power offered by cQLS will be lowered. Therefore, the additional
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computational cost would offer less value. Second, we have examined cQLS
only in nuclear families and simple three-generation families (data not shown)
where IBD can be reconstructed with high accuracy. We need further test-
ing to assess the quality of IBD estimates from more distant relationships.
Third, cQLS tests for association and, unlike FBAT, will have no power
when there is linkage but no association. Although sequencing has removed
our reliance on tag SNPs, a linkage analysis may still offer advantages in the
presence of epistasis.
Finally, we remark that there is no consensus on how to best combine
within-family and between-family information in GWAS with related in-
dividuals. However, a technical way to address this question would be to
examine the full-data likelihood. The derivation of the cQLS (Appendix B)
starts by defining this likelihood. The form of the final test statistic is the
likelihood ratio test statistic based on the key partial likelihood, suggest-
ing that the cQLS offers a near optimal combination of the two types of
information.
APPENDIX A: MQLS AND FBAT
We compared the performance of a cQLS test to two standard tests:
mQLS [Thornton and McPeek (2007)] and FBAT [Laird, Horvath and Xu
(2000)]. mQLS is a quasi-likelihood score statistic that presumes an indi-
vidual’s expected genotype increases with the sum, over all affected family
members, of their kinship coefficients with that individual. A complete, but
terse, definition follows.
For purposes of defining mQLS, we assume there are n =Ng +M total
subjects, of which Ng have been genotyped. We let Φ be the (Ng +M)×
(Ng+M) matrix of kinship coefficients and ΦN,M be the submatrix contain-
ing the last M columns of the first Ng rows. The phenotype data are coded
as A‡, a column vector of length Ng+M having ith entry 1 if individual i is
affected, 0 if unknown and πˆ0/(1− πˆ0) otherwise. A
‡
N is the vector containing
the first Ng elements (e.g., genotyped individuals) and A
‡
M contains the last
M elements. Let G be the vector of observed genotypes ( 12Gi ∈ {0,0.5,1})
for the first Ng individuals. Finally, let 1 be a column vector of 1’s. Then
mQLS is defined as
mQLS= σˆ−2(12G− µˆ0)
TαΓ−1αT (12G− µˆ0),(A.1)
where
α=A‡N +Φ
−1ΦN,MA
‡
M ,(A.2)
Γ = αT (ΦA‡n +ΦN,MA
‡
M )− (1
Tα)2(1TΦ−11T )−1,(A.3)
µˆ0 = pˆnull1,(A.4)
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σˆ−20 = [
1
2 pˆnull(1− pˆnull)]
−1,(A.5)
pˆnull =
1
2(1
TΦ−11)−11TΦ−1G.(A.6)
For implementation, we downloaded the software from http://galton.
uchicago.edu/~mcpeek/software/MQLS/index.html and, in simulations,
set the prevalence of the disease to the “true” value.
FBAT compares the genotypes observed in the cases to their expected
value under the null hypothesis of “no linkage and no association” or “no as-
sociation, in the presence of linkage,” conditioned on the parent’s genotypes
(or the appropriate sufficient statistic if parental genotypes are unknown).
For details, we suggest the user’s manual for the software downloadable from
http://www.biostat.harvard.edu/~fbat/default.html.
APPENDIX B: CQLS: DERIVATION
B.1. Model assumptions. Without loss of generality, we can assume that
all Nind individuals come from the same family, and therefore drop the sub-
script j from notation. We further define Θ to be the set of parameters in the
model, including those defining the SNP’s effect on the disease. All notation
and discussion assume a single SNP under study.
We will assume random mating.
We will assume
P [Ai = 1|Gi = 2,Xi,Θ] =H
2
i P [Ai = 1|Gi = 0,XiΘ],
where Gi is defined as the genotype, or the number of minor alleles, for
individual i, Xi is a vector of covariates, Θ is a set of parameters, and
Hi =
P [Ai = 1|Gi = 1,Xi]
P [Ai = 1|Gi = 0,Xi]
.(B.1)
The immediate consequence is that
P [Ai = 0|Gi = 2,Xi,Θ] = (1− πi)
[
1−Hiπi
1− πi
]2
+
πi
1− πi
(Hi − 1)
2,
where πi is the probability individual i is affected.
For purposes of deriving our test statistic, we further assume that (πi/(1−
πi))(Hi − 1)
2 is small or that we can treat the following approximation as
an equality without issue:
P [Ai = 0|Gi = 2,Xi,Θ]≈
(
1−Hiπi
1− πi
)2
P [Ai = 0|Gi = 0,Xi].
The properties of the test statistic, such as being distributed as a χ21
variable under the null, will not depend on this approximation holding.
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These approximations give us two simplifying results:
P [Y1, . . . , Yn|A,X,M
∗,Θ] =
∏
k
P [Yk|A,X,M
∗,Θ](B.2)
P [Yk = 1|A,X,M
∗,Θ] =
p
∏
i h
∑
k′ Tik′k
i
1 + p
∏
i h
∑
k′ Tik′k
i
,(B.3)
where hi =HiAi + (1−Hiπi)(1− πi)
−1(1−Ai), p = P [Yi = 1]/P [Yi = 0] =
φ/(1 − φ) and M∗ = {Tik′k : i ∈ 1, . . . ,Nind, k
′ ∈ {1,2}, k ∈ {1, . . . , n}} is the
IBD architecture. We will derive equations (B.2) and (B.3) in a later section
of the Appendix.
B.2. Probability and score. We are interested in the distribution of Y
and MO given A, X, S and Θ. Here, S is a vector indicating that the
individuals were selected for the study and MO are the observed values of
M
∗. The variables Tik′k cannot be identified in family members that are
phenotyped, but not genotyped. We have chosen to treat Y as the outcome
because we will not need to know the selection procedure used to choose
families and we do not need to estimate the nuisance parameter that is the
correlation of disease status in the family due to nongenetic similarities. We
do note that a full probability would be P [Y,MO,A,X|S,Θ] and we ignore
P [A,X|S,Θ] because it carries little information about Θ:
P [Y,MO|A,X, S, θ] = P [Y|A,X,MO, S, θ]P [MO|A,X, S, θ].
However, we consider only the conditional probability, as this half is far more
sensitive to Θ. Also, although not mentioned above, we will make the addi-
tional assumption that, conditional on all other information, the genotypes
and the characteristics used to select the individuals are independent. Then
we know that S drops out of the desired probability:
P [Y|A,X,MO, S,Θ] =
P [Y, S|A,X,MO,Θ]
P [S|A,X,MO,Θ]
(B.4)
= P [Y|A,X,MO,Θ].
In an upcoming section, we will show that the score statistic for P [Y|A,X,
M
O,Θ] is defined by equation (2.6) when M∗ is known.
B.3. Mathematical detail.
B.3.1. Detail for Section B.1. We first demonstrate equation (B.2):
P [Y1, . . . , Yn1 |A,X,M
∗,Θ](B.5)
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=
P [A|Y1, . . . , Yn1 ,X,Θ]
∏
k P [Yk]
P [A|X,M∗,Θ]
(B.6)
=
P [A|Y = 0,X,Θ]
∏
k
∏
i h
∑
k′ Gik′T
M∗
ik′k
i P [Yk]
P [A|M,X,Θ]
(B.7)
=
∏
k
P [Yk|A,M,X,Θ].(B.8)
We next demonstrate equation (B.3), where we let Y−k be the vector of
all alleles except for k:
P [Yk = 1|A,X,M
∗,Θ](B.9)
= P [Yk = 1|A,X,M
∗,Θ,Y−k](B.10)
=
P [A|Y−k, Yk = 1,X,M
∗,Θ]P [Yk = 1]
P [A|Y−k,X,M∗,Θ]
(B.11)
=
(
P [A|Y−k, Yk = 1,X,M
∗,Θ]
P [A|Y−k, Yk = 0,X,M∗,Θ]
P [Yk = 1]
P [Yk = 0]
×P [A|Y−k, Yk = 0,X,M
∗,Θ]P [Yk = 0]
)
(B.12)
/
P [A|Y−k,X,M
∗,Θ]
=
P [A|Y−k, Yk = 1,X,M
∗,Θ]
P [A|Y−k, Yk = 0,X,M∗,Θ]
P [Yk = 1]
P [Yk = 0]
P [Yk = 0|A,X,M
∗,Θ](B.13)
=
∏
i h
∑
k′ Tik′k
i P [Ai|Y−k, Yk = 0,X,M
∗,Θ]∏
iP [Ai|Y−k, Yk = 0,X,M
∗,Θ]
P [Yk = 1]
P [Yk = 0]
(B.14)
×P [Yk = 0|A,X,M
∗,Θ]
=
∏
i
h
∑
k′ Tik′k
i
P [Yk = 1]
P [Yk = 0]
P [Yk = 0|A,X,M
∗,Θ].(B.15)
B.3.2. Score statistic: Yjk and M
∗ can be uniquely identified. The over-
all probability can be written as the product of the probabilities for each
chromosome with the assumptions in place:
P [Y|D,p,Θ] =
∏
k
P [Yk|D,p,Θ],(B.16)
where D abbreviates the collected data, D = {A,X,M∗}.
Because we must account for the nuisance parameter p, the score statistic
for Θ is equation (B.17) evaluated under the null hypothesis
−
[∑
k
d
dΘ
ℓD(Yk)
∑
k
d
dp
ℓD(Yk)
]
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(B.17)
×


∑
k
d
d2Θ
ℓD(Yk)
∑
k
d
dΘdp
ℓD(Yk)
∑
k
d
dΘdp
ℓD(Yk)
∑
k
d
d2p
ℓD(Yk)


−1

∑
k
d
dΘ
ℓD(Yk)
∑
k
d
dp
ℓD(Yk)

 ,
where
ℓD(Yk) = log(P [Yk|A,X,M
∗, p,Θ]).(B.18)
It is straightforward to evaluate the needed derivative
U ≡
∑
k
d
dΘ
∣∣∣∣
H0
ℓD(Yk) =
∑
k
Zk(Yk − φˆ),(B.19)
φˆ=
∑
k Yk∑
k 1
,(B.20)
where
Zk ≡
∑
i
∑
k′
Tik′k
h˙i
hi
,(B.21)
h˙i =
d
dΘ
hi.(B.22)
We can rewrite U , so that we can calculate its variance, σ2U , without
computing/inverting the matrix in equation (B.17):
U ≡
∑
k
d
dΘ
∣∣∣∣
H0
ℓD(Yk) =
∑
k
(Zk − Z¯)(Yk − φˆ),(B.23)
Z¯ =
∑
kZk∑
k 1
,(B.24)
σ2U = φ(1− φ)
∑
k
(Zk − Z¯)
2.(B.25)
B.3.3. Score statistic: All individuals are not genotyped and M∗ cannot
be uniquely identified. When all family members are not genotyped, the
probability must be averaged over the B possible IBD states
P [Y|A,X,MO, p,Θ]
(B.26)
=
B∑
b=1
P [Y|A,X,M∗ =mb, p,Θ]P [mb|M
O].
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We can take advantage of the equality
d
dΘ
∣∣∣∣
H0
log
(∑
b
cbP [Y|D(mb), p,Θ]
)
(B.27)
=
d
dΘ
∣∣∣∣
H0
∑
b
cb log(P [Y|D(mb), p,Θ]),
where we use the abbreviation cb = P [mb|M
O] and use D(mb) because M
∗
is no longer known.
Equation (B.27) shows us that the score for P [Y|A,X,MO, p,Θ] is pro-
portional to the score we would observe had there been NM families, where
all families had the observed Y and cbNM of those families had IBD struc-
ture mb. Therefore, equation (B.19) still holds, so long as we now let
Zk ≡
∑
i
∑
k′
P [Tik′k = 1]
h˙i
hi
.(B.28)
B.3.4. Score statistic: Yjk cannot be uniquely identified. In some scenar-
ios, Yk cannot be uniquely identified given the available genetic information.
In these scenarios, we must average the two possibilities to obtain the value
of cQLS. As an example, this situation occurs in our simulated studies of
sibling pairs. When two siblings have IBD= 1 and are each heterozygous, we
cannot determine whether the shared chromosome has the minor or common
allele. We focus on this specific example to explain the needed adjustment.
Let Qj = 1 if the siblings have IBD = 1 and are both heterozygous. Fur-
thermore, in such a family, let Y1, Y2 and Y3 denote the alleles on the chro-
mosome uniquely in the first brother, in both brothers and uniquely in the
second brother, respectively. Let Z1, Z2 and Z3 be the disease variable for
each of those chromosomes. We know
P (Q= 1|A,X,M∗, p,Θ)(B.29)
= P ({Y1, Y2, Y3}= {1,0,1}|A,X,M
∗, p,Θ)(B.30)
+P ({Y1, Y2, Y3}= {0,1,0}|A,X,M
∗, p,Θ).(B.31)
For families with Q= 1, we must reevaluate their contribution to the score
equations. Under the null hypothesis, we find
d log(P (Q= 1|A,X,M∗, p,Θ))
dp
∣∣∣∣
H0
(B.32)
= (2− φ)
−φ2/p2
1− φ
+ (1 + φ)
φ
p2
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and
d log(P (Q= 1|A,X,M∗, p,Θ))
dΘ
∣∣∣∣
H0
= (1− 2φ)Z2.(B.33)
Our new contributions to the score equations lead us to the following
MLE of φ:
φˆ=
N1 +N3
N0 +N1 +N3
,(B.34)
where
N0 =
∑
j,k
1(Qj = 0)1(Yjk = 0),(B.35)
N1 =
∑
j,k
1(Qj = 0)1(Yjk = 1),(B.36)
N3 =
∑
j,k
1(Qj = 1).(B.37)
Furthermore, we can rewrite U as
U =
∑
j,k:Qj=1
(Zk − Z¯)(Yk − φˆ) +
∑
j:Qj=0
(1− 2φˆ)(Z2 − Z¯)(B.38)
and the score statistic as
U2
σˆ2U
,(B.39)
where we let pu be the unique probabilities of each of the eight possible
combinations of {Y1, Y2, Y3} when IBD= 1, Zj∗ be the possible correspond-
ing contributions from family j, and σˆ2U be the appropriate estimate of the
variance under the null:
pu1 = φˆ
3,(B.40)
pu2 = φˆ
2(1− φˆ),(B.41)
pu3 = φˆ(1− φˆ)
2,(B.42)
pu4 = (1− φˆ)
3,(B.43)
Z∗j1 =
(
3∑
k=1
(Zk − Z¯)(1− φˆ)
)2
,
Z∗j2 =
(
3∑
k=1
(Zk − Z¯)(1− φˆ)−Z3 + Z¯
)2
+ ((Z2 − Z¯)(1− φ))
2
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+
(
3∑
k=1
(Zk − Z¯)(1− φˆ)−Z1 + Z¯
)2
,
Z∗j3 =
(
3∑
k=1
(Zk − Z¯)(1− φˆ)−Z2 −Z3 + 2Z¯
)2
+ ((Z2 − Z¯)(1− φ))
2
+
(
3∑
k=1
(Zk − Z¯)(1− φˆ)−Z1 −Z2 + 2Z¯
)2
,
Z∗j4 =
3∑
k=1
((Zk − Z¯)(−φˆ))
2
and
σˆ2U = φˆ(1− φˆ)
∑
j,k:IBD(j)6=1
(Zk − Z¯)
2 +
∑
j:IBD(j)=1
4∑
t=1
putZ∗jt.(B.44)
Accurate haplotyping would overcome this difficulty and allow us to
uniquely identify Yjk. As we expect haplotyping to become standard prac-
tice in the very near future [Peters et al. (2012)], we expect that this step
will soon be unnecessary.
B.3.5. Violation of the Hardy–Weinberg Equilibrium. Our estimate for
the variance of U in equation (B.25) assumes that the genotypes are in
HWE. As an alternative, start by calculating the 16 possible values (one for
each genotype) of U =
∑
k(Zk − Z¯)(Yk − φˆ) for each family j. The second
step is to calculate the probability of each of the 16 genotypes. Given these
probabilities and the possible values of U , it is straightforward to calculate
the variance of U for any family under the null hypothesis, conditional on
IBD architecture. Currently, this alternative is only available for families
with at most four founding chromosomes (e.g., nuclear families) and, there-
fore, the remaining goal is to estimate p = {p200, p110, p101, p020, p011, p002},
where pxyz is the probability that the founding individuals include x, y and
z individuals with genotypes Gi = 0, Gi = 1 and Gi = 2. We estimate these
six probabilities by effectively maximizing P (Y |MO, p) with the constraints
that pxyz ≥ 0 and that 0.25p110 + 0.5p020 + 0.5p101 + 0.75p011 + p002 = φˆ.
Specifically, we minimize the following function:
2
(∑
j
1(nj = 2)
)
(M2V2 −A2)
2 + 3
(∑
j
1(nj = 4)
)
(M3V3 −A3)
2
(B.45)
+ 4
(∑
j
1(nj = 4)
)
(M4V4 −A4)
2,
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where M4 is a 6× 6 identity matrix,
M2 =

1 0.5 0.25 0 0 00 0.5 0.5 1 0.5 0
0 0 0.25 0 0.5 1

 and
M3 =


1 0.25 0 0 0 0
0 0.5 0.5 0.5 0 0
0 0 0.5 0.5 0.5 0
0 0 0 0 0.25 1
0 0.25 0 0 0.5 0


and V2 is the vector estimating {P (
∑
k Yk = 0|nj = 2), P (
∑
k Yk = 1|nj =
2), P (
∑
k Yk = 2|nj = 2)}, V3 estimates {P (
∑
k Yk = 0|nj = 3), P (
∑
k Yk =
1,W = 1|nj = 3), P (
∑
k Yk = 2,W = 1|nj = 3), P (
∑
k Yk = 3|nj = 3),
P (
∑
k Yk = 2,W = 0|nj = 3)}, V4 estimates {P (
∑
k Yk = 0|nj = 4),
P (
∑
k Yk = 1|nj = 4), P (
∑
k Yk = 1,G2 = 1|nj = 4), P (
∑
k Yk = 1,G2 6= 1|nj =
4), P (
∑
k Yk = 3|nj = 4), P (
∑
k Yk = 4|nj = 4)}, W is a binary variable in-
dicating whether all alleles are identifiable, and {G1,G2} are the founder
genotypes.
B.4. Algorithm for assigning Tijk′k. We start by arbitrarily assigning
numbers to the chromosomes of the founder individuals and trimming the
family so that no two individuals have IBD = 2. Founder individuals are
defined to be the largest group possible such that all pairs of founder indi-
viduals have IBD= 0. Let A be initialized as the founder individuals.
Find an individual, i3, in the compliment of A, that meets the first of
the following possible criteria and follow the assignment mechanism. Add
individual i3 to A and then repeat.
(a) i3 has IBD = 1 with two individuals in A, say, i1 and i2, that are also
IBD = 1 with each other. Count the number of minor alleles, among
individuals i1, i2 and i3, at all loci in the shared region. Assume chro-
mosomes in individuals i1 and i2 have been labeled as {1,2} and {1,4}.
Option (a1). If (nearly) all counts are even, the chromosomes in indi-
vidual i3 are assigned as {2,4}.
Option (a2). (Nearly). All counts are not even, and individual i3 is ei-
ther IBD = 0 with all other individuals in A or IBD = 1 only with
individuals who are IBD = 1 with both i1 and i2. Then the chro-
mosomes in i3 are labeled as {1,X}, where X is a new chromosome
number.
Option (a3). (Nearly). All counts are not even, and individual i3 is
IBD = 1 with at least two more individuals in A, say, i4 and i5,
that are IBD = 1 with each other, but IBD = 0 with both i1 and i2.
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Then the chromosomes in i3 are labeled as {1,5}, where we assume
the chromosomes in i4 and i5 are labeled as {5,6} and {5,8}.
Option (a4). (Nearly). All counts are not even, and individual i3 is
IBD = 1 with exactly one other individual in A, say, i4, that is
IBD = 0 with both i1 and i2. Then, we label i3 as {1,5}, where the
chromosomes in individuals i4 have been labeled as {5,6}.
(b) i3 has IBD = 1 with two individuals in A, say, i2 and i3, that share
IBD = 0 with each other.
Option (b1). Individual i1 (or i2) has IBD = 1 with another individual
in A, say, i4, in A. Then, we label i3 as {2,3}, where the chromo-
somes in individuals i1, i2 and i4 have been labeled as {1,2}, {3,4}
and {1,6}.
Option (b2). Individual i1 and i2 have IBD = 0 with all other individ-
uals in A. Then, we label i3 as {1,3}, where the chromosomes in
individuals i1 and i2 have been labeled as {1,2} and {3,4}.
(c) i3 has IBD = 1 with only one individual in A, say, i1.
Option (c1). Individual i1 has IBD = 1 with another individual in A,
say, i2. Assign the chromosomes in individual i3 as {2,X}, where
the chromosomes in individuals i1 and i2 have been labeled as {1,2}
and {1,4} and X is a new chromosome number.
Option (c2). Individual i1 has IBD = 0 with all other individuals in
A. Assign the chromosomes in individual i3 as {2,X}, where the
chromosomes in individuals i1 have been labeled as {1,2} and X is
a new chromosome number.
B.5. Limitations. The standard method for finding an optimal test statis-
tic starts by defining the parameter of interest and then writing out the
likelihood of the observed data given this, and possibly other, parameters.
In the GWAS discussed here, such a likelihood would necessarily bridge the
within-family and between-family information, and immediately show how
the two pieces of information should be combined. Here, we have defined
this likelihood and shown that the cQLS is derived as the score statistic to a
specific partial likelihood. However, as that likelihood shows, we ignore infor-
mation that can be derived from the observed IBD structure. For example,
if all affected siblings are IBD = 2 at a SNP, that provides some evidence
of an association between SNP and disease. Although that information is
minimal, we are currently looking into methods for capturing and including
this independent information as well. By using only the partial likelihood,
the cQLS is not guaranteed to result in the most powerful test.
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